Eli Lilly's weight-loss therapy Mounjaro tops India drug sales by value in October
Opinion: Opinion | The Rich Get Fit, And Poor Get 'Lectures' - That's India's Ozempic Problem
Rybelsus, Mounjaro, Wegovy: India's weight-loss drug boom and the risks behind it
explain mounjaro in 500 words
- Mounjaro is a medication primarily used for the management of type 2 diabetes. Its generic name is tirzepatide, and it is a novel therapeutic agent that has gained attention for its dual action on glucose regulation and weight management. Developed by Eli Lilly and Company, Mounjaro was approved by the U.S. Food and Drug Administration (FDA) in May
- Tirzepatide belongs to a class of drugs known as GLP-1 receptor agonists, which mimic the action of the incretin hormones in the body. Incretins are hormones released by the intestines in response to food intake that help regulate blood sugar levels. Specifically, GLP-1 (glucagon-like peptide-1) helps increase insulin secretion, suppress glucagon release (a hormone that raises blood glucose levels), slows gastric emptying, and promotes satiety. Mounjaro is unique because it also acts on another receptor, GIP (gastric inhibitory polypeptide), which further enhances its effects on glycemic control and weight loss.
- The dual-action mechanism of Mounjaro allows it to address both hyperglycemia (high blood sugar) and obesity, which are common challenges faced by individuals with type 2 diabetes. Clinical trials have demonstrated that Mounjaro significantly reduces HbA1c levels (a measure of average blood glucose over the past two to three months) and promotes substantial weight loss in patients. In fact, some studies have shown that patients using Mounjaro experienced greater weight loss compared to those on traditional diabetes medications.
- Mounjaro is administered via subcutaneous injection, typically once a week. The dosing can be initiated at a lower level, with gradual increases based on the patient’s response and tolerability. This titration approach helps minimize gastrointestinal side effects, which are common with GLP-1 receptor agonists. Side effects can include nausea, vomiting, diarrhea, and decreased appetite, but these tend to diminish over time as the body adjusts to the medication.
- In addition to its primary indications, Mounjaro is being studied for potential use in other areas, including cardiovascular health and weight management in non-diabetic populations. Early research suggests that tirzepatide may have beneficial effects on cardiovascular risk factors, making it a promising option for patients with coexisting conditions.
- It's important to note that Mounjaro is not suitable for everyone. It is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type Additionally, patients should be monitored for pancreatitis and kidney function, as these can be concerns with GLP-1 receptor agonists.
- Overall, Mounjaro represents a significant advancement in the treatment landscape for type 2 diabetes, offering a new mechanism of action that not only helps manage blood glucose levels but also assists in weight loss. As with any medication, it is essential for patients to work closely with their healthcare providers to determine the best treatment plan tailored to their individual needs, considering potential risks and benefits. With the ongoing research and development in diabetes care, Mounjaro may pave the way for more innovative approaches to managing this chronic condition.